Combination of Anti-PD-1 and NK Immunotherapy for Recurrent Solid Tumors

NCT02843204 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

110

Enrollment

OTHER

Sponsor class

Conditions

Malignant Solid Tumour

Interventions

DRUG: Pembrolizumab
BIOLOGICAL: NK immunotherapy

Sponsor

Fuda Cancer Hospital, Guangzhou

Collaborators

[object Object]